Impact of fluoxetine on liver damage in rats

Pharmacological Reports

Volumn 63, Issue 2, 2011, Pages 441-447

  Inkielewicz Stêpniak, Iwona ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

ALAT; AST; Fluoride; Fluoxetine; GST; Liver; Male rats; Oxidative stress parameters

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBONYL DERIVATIVE; FLUOXETINE; GLUTATHIONE TRANSFERASE; TAP WATER; THIOBARBITURIC ACID REACTIVE SUBSTANCE; URIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; LIPID PEROXIDATION; LIVER INJURY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT;

EID: 79955931363     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70510-2     Document Type: Article

References (46)

1. Abuja PM: Ascorbate prevents prooxidant effects of urate in oxidation of human low-density lipoprotein. FEBS Let, 1999, 446, 305-308.
2. Adachi Y, Horii K, Suwa M, Tanihata M, Ohba Y, Yamamoto T: Serum glutathione S-transferase in experimental liver damage in rats. J Gastroenterol, 2007, 16, 129-133.
3. Afzali A,Weiss NS, Boyko EJ, Ioannou GN: Association between serum uric acid level and chronic liver disease in the United States. Hepatology, 2010, 52, 578-589.
4. Anosike EO, Uwakwe AA, Monanu OM, Ekeke GI: Studies on human erythrocytes glutathione-s- transferase from Hb AA Hb AS and Hb SS subject. Biomed Biochim Acta, 1991, 50 1051-1056.
5. Aranth J, Lindberg C: Bleeding as a side effect of fluoxetine. Am J Psychiatry, 1992, 149, 412.
6. Bass SP, Colebatch HJH: Fluoxetine-induced lung damage. Med J Aust, 1992, 156, 364-365.
7. Beasley CM Jr, Nilsson ME, Koke SC, Gonzales JS: Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. J Clin Psychiatry, 2000, 61, 722-728.
8. Bendele RA, Adams ER, Hoffman WP, Gries CL, Morton DM: Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res, 1992, 52, 6931-6935.
9. Bergmeyer HU, Herder M, Rej R: Approved recommendation 1985 on IFCC methods for the measurement of catalytical concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase. J Clin Chem Clin Biochem, 1986, 24, 497-510.
10. Bergmeyer HU, Herder M, Rej R: Approved recommendation 1985 on IFCC methods for the measurement of catalytical concentration of enzymes. Part 3. IFCC method for alanine aminotransferase. J Clin Chem Clin Biochem, 1998, 24, 481-489.
11. Berlett BS, Stadtman ER: Protein oxidation in aging, disease, and oxidative stress. J Biol Chem, 1997, 272, 20313-20316. (Pubitemid 27355575)
12. Bulgar HA, Johns HE: The determination of plasma uric acid. J Biol Chem, 1941, 140, 427-440.
13. Cao G, Cutler RG: Protein oxidation and aging. I. Difficulties in measuring reactive protein carbonyls in tissues using 2,4- dinitrophenylhydrazine. Arch Biochem Biophys, 1995, 320, 106-114.
14. Capella D, Bruguera M, Figueras A, Laporte J: Fluoxetine- induced hepatitis: why is postmarketing surveillance needed? Eur J Clin Pharmacol, 1999, 55, 545-546.
15. Castiella A, Arenas J: Fluoxetine hepatotoxicity. Am J Gastroenterol, 1994, 89, 458-459.
16. Curzon G, Gibson EL, Oluyomi AO: Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci, 1997, 18, 22-25.
17. Czarnowski W, Wrzeoeniowska K, Krechniak J: Fluoride in drinking water and human urine in Northern and Central Poland. Sci Total Environ, 1996, 191, 177-184. (Pubitemid 26336587)
18. Dolfing JG, Bruce HR,Wolffenbuttel BHR, Hoor- Aukema NM, Schweitzer DH: Daily high doses of fluoxetine for weight loss and improvement in lifestyle before bariatric surgery. Obesit Surg, 2005, 15, 1185-1191. (Pubitemid 41390219)
19. Feder R: Bradycardia and syncope induced by fluoxetine. J Clin Psychiatry, 1991, 52, 139.
20. Feldman M, Friedman LS, Brandt LJ: Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 8th edn., Saunders Elsevier, Philadelphia, Pa. 2006, 1575.
21. Folin O, Morris JL: On the determination of creatine and creatinine in urine. J Biol Chem, 1914, 17, 469-473.
22. Friedenberg FK, Rothstein KD: Hepatitis secondary to fluoxetine treatment. Am J Psychiatry, 1996, 153, 580.
23. Gałecki P, Szemraj J, Bieńkiewicz M, Florkowski P, Gałecka E: Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep, 2009, 61, 436-447.
24. Gamaro GD, Prediger ME, Lopes J, Bassani MG, Dalmaz C: Fluoxetine alters feeding behavior and leptin levels in chronically-stressed rats. Pharmacol Biochem Behav, 2008, 90, 312-317.
25. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA: Uric acid and oxidative stress. Curr Pharm Des, 2005, 32, 4145-4151. (Pubitemid 41672464)
26. Guze BH, Gitlin M: New antidepressants and the treatment of depression. J Fam Pract, 1994, 38, 49-57. (Pubitemid 24027980)
27. Halliwell B, Chirico S: Lipid peroxidation: Its mechanism, measurement, and significance. Am J Clin Nutr, 1993, 57, 715-725.
28. Hayden MR, Tyagi SC: Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond), 2004, 1, 10-25.
29. Henry ME, Schmidt ME, Hennen J, Rosemond A, Villafuerte RA, Butman ML, Tran P et al.: A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. Neuropsychopharmacology, 2005, 30, 1576-1583
30. Inkielewicz I, Krechniak J: Fluoride effects on glutathione peroxidase and lipid peroxidation in rats. Fluoride, 2004, 37, 7-12. (Pubitemid 38899364)
31. Johnston DE, Wheeler DE: Chronic hepatitis related to use of fluoxetine. Am J Gastroenterol, 1997, 92, 1225-1226. (Pubitemid 27304831)
32. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, Mancini M, Trevisan M: Serum uric acid and hypertension: the Olivetti Heart Study. J Hum Hypertens, 1994, 8, 677-681 (Pubitemid 24276965)
33. Lee-Lewandrowski E, Lewandrowski K: The plasma protein. In: Clinical Laboratory Medicine. Ed. Kenneth D. McClatchey, Williams and Wilkins, Baltimore, 1994, 239.
34. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW et al.: Determination of carbonyl content in oxidatively modified proteins. In: Methods in Enzymology. Ed. Pecker L, Glazer AN, Academic Press, New York, 1990, 186, 464-478.
35. Llerena A, Dorado P, Berecz R, González A, Norberto MJ, Rubia A, Cáceres M: Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. J Chromatogr B, 2003, 783, 25-31. (Pubitemid 35351629)
36. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem, 1951, 193, 265-275.
37. Mars F, Dumas de la Roque G, Goissen P: Acute hepatitis during treatment with fluoxetine. Gastroenterol Clin Biol, 1991, 15, 270-271.
38. Pacifici RE, Davies KJA: Protein degradation as an index of oxidative stress. Methods Enzymol, 1990, 186, 485-502. (Pubitemid 20279991)
39. Park BK, Kitteringham NR, O'Neill PM: Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol, 2001, 41, 443-470. (Pubitemid 32385895)
40. Rice-Evans CA, Diplock AT, Symons MCR: Techniques in free radical research. Elsevier, Amsterdam, 1991.
41. Saletu B, Grunberger T: Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analysis. J Clin Psychiatry, 1985, 46, 45-52 (Pubitemid 15139190)
42. Souza ME, Polizello AC, Uyemura SA, Castro-Silva O, Curti C: Effect of fluoxetine on rat liver mitochondria. Biochem Pharmacol, 1994, 48, 535-541. (Pubitemid 24257016)
43. Strunecká A, Patoèka J, Connett P: Fluorine in medicine. J Appl Biomed, 2004, 2, 141-150.
44. Thompson DC, Perera K, London R: Spontaneous hydrolysis of 4-trifluoromethylphenol to a quinone methide and subsequent protein alkylation. Chem-Biol Interact, 2000, 126, 1-14. (Pubitemid 30417476)
45. Zafir A, Ara A, Banu N: In vivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry, 2009, 33, 220-228.
46. Zafir A, Banu N: Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed. Eur J Pharmacol, 2007, 572, 23-31.